USA, Fishers-based Genezen has raised $18.5 million in Growth Equity funding, led by Ampersand Capital Partners. Specializing in cell and gene therapy contract development and manufacturing, Genezen aims to use the funds to enhance its viral vector development and manufacturing capacity. With CEO and President Steven Favaloro at the helm, the company recently concluded the qualification of its 25,000 sq ft GMP viral vector facility in Fishers, Indiana, positioning itself for further growth in the dynamic field of cell and gene therapy.